Research programme: bispecific monoclonal antibodies - Amgen/Xencor

Drug Profile

Research programme: bispecific monoclonal antibodies - Amgen/Xencor

Alternative Names: Bispecific anticancer and antiinflammatory monoclonal antibodies; XmAb bispecific x5; XmAb13551; XmAb14702; XmAb15426

Latest Information Update: 19 Oct 2015

Price : $50

At a glance

  • Originator Amgen; Xencor
  • Class Anti-inflammatories; Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action CD3 antigen inhibitors; CD38 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Multiple myeloma
  • Research Cancer; Inflammation

Most Recent Events

  • 16 Sep 2015 Amgen and Xencor collaborate on development of anticancer and anti-inflammatory therapeutics
  • 16 Sep 2015 Early research in Cancer in USA (unspecified route)
  • 16 Sep 2015 Early research in Inflammation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top